Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
1 report, 1 independent
Updated Sep 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Also in this story
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.
- Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.
- Mineralys Therapeutics presented its clinical trial results at the American Heart Association sessions in Baltimore.
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
-
Novartis
Swiss-American multinational pharmaceutical corporation